Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Redmile Group, LLC 13F Holdings -- Portfolio & Top Positions (2026-03-31)

Redmile Group, LLC (CIK 1425738) reported $1.51B across 34 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: SRRK ($445.7M, 29.51%), KRYS ($174.0M, 11.52%), STOK ($135.6M, 8.98%), IMNM ($121.6M, 8.05%), NRIX ($119.9M, 7.94%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1SRRKSCHOLAR ROCK HLDG CORP$445.7M29.51%9.1MAdded
2KRYSKRYSTAL BIOTECH INC$174.0M11.52%673,505Trimmed
3STOKSTOKE THERAPEUTICS INC$135.6M8.98%4.2MAdded
4IMNMIMMUNOME INC$121.6M8.05%5.6MTrimmed
5NRIXNURIX THERAPEUTICS INC$119.9M7.94%7.7MTrimmed
6ANNXANNEXON INC$80.6M5.34%14.5MAdded
7ADCTADC THERAPEUTICS SA$58.0M3.84%15.5MTrimmed
8RGNXREGENXBIO INC$36.6M2.42%4.4MHold
9STTKSHATTUCK LABS INC$35.6M2.36%5.5MHold
10BEAMBEAM THERAPEUTICS INC$29.5M1.95%1.2MTrimmed
11NGNENEUROGENE INC$29.4M1.95%1.5MHold
12COGTCOGENT BIOSCIENCES INC$26.5M1.75%688,036Trimmed
13ABSIABSCI CORPORATION$24.8M1.64%8.3MHold
14IDYAIDEAYA BIOSCIENCES INC$17.4M1.15%521,117Trimmed
15ALXOALX ONCOLOGY HLDGS INC$16.0M1.06%8.0MAdded
16FATEFATE THERAPEUTICS INC$15.4M1.02%12.9MHold
17XENEXENON PHARMACEUTICALS INC$15.3M1.01%262,674Added
18SLDBSOLID BIOSCIENCES INC$14.5M0.96%2.0MAdded
19NUVBNUVATION BIO INC$13.5M0.90%3.2MTrimmed
20ZYMEZYMEWORKS INC$12.3M0.82%491,654Hold
21SLNSILENCE THERAPEUTICS PLC$11.4M0.76%2.2MHold
22DBVTDBV TECHNOLOGIES S A$10.3M0.68%491,340Trimmed
23BMRNBIOMARIN PHARMACEUTICAL INC$9.8M0.65%173,859New
24CLDXCELLDEX THERAPEUTICS INC NEW$8.3M0.55%261,508Trimmed
25CBLLCERIBELL INC$7.1M0.47%386,786Trimmed

Source: SEC Form 13F filings · as of 2026-03-31